An observational study in Autoimmune Thyroiditis and Recurrent Miscarriage, sponsored by Zonguldak Bulent Ecevit University. Completed at 1 site in Turkey. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-01-11.
Sponsored by Zonguldak Bulent Ecevit University · Observational
The aim of this study is to compare the thyroid hormone values and anti-thyroid peroxidase (anti-TPO) levels of women with a diagnosis of recurrent pregnancy loss (RPL) and healthy pregnancies. The primary objective is to find out the relationship between recurrent pregnancy loss with thyroid hormone levels and anti-TPO positivity.
27 studies on the registry are indexed under Thyroiditis, Autoimmune; 4 are open to participants now.
Browse Thyroiditis, Autoimmune studies →Zonguldak Bulent Ecevit University is the lead sponsor of 100 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study was carried out with a total of 103 patients by retrospectively examining the patients who applied to the Gynecology and Obstetrics Clinic of Bülent Ecevit University Faculty of Medicine between 2018-2022
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients with a diagnosis of recurrent miscarriage
healthy women at same age and similar demographics
Anti-thyroid Peroxidase Antibodies
presence of Anti-thyroid Peroxidase Antibodies in both groups
Time frame: 4 years
Thyroid Hormone Levels
levels of Thyroid stimulant Hormone, Thyroxin and triiodothyronine levels
Time frame: 4 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zonguldak Bulent Ecevit University →